Features of sepsis caused by pulmonary infection with Francisella tularensis Type A strain

Microbial Pathogenesis

Volumn 51, Issue 1-2, 2011, Pages 39-47

  Sharma, Jyotika ^a   Mares, Chris A ^a   Li, Qun ^a   Morris, Elizabeth G ^a   Teale, Judy M ^a,b  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Alarmin; Bacteremia; Hypercytokinemia; SchuS4; Sepsis; Tularemia

Indexed keywords

BACTERIAL TOXIN; CALGRANULIN B; CXCL2 CHEMOKINE; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BLOOD CLOTTING DISORDER; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE STORM; FRANCISELLA TULARENSIS; IMMUNE RESPONSE; INNATE IMMUNITY; LUNG HOMOGENATE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SEPSIS; TISSUE DISTRIBUTION; UPREGULATION;

ANIMALS; BACTEREMIA; CYTOKINES; FRANCISELLA TULARENSIS; HUMANS; INFLAMMATION; LIVER; LUNG; LUNG DISEASES; MICE; MICE, INBRED C57BL; SEPSIS; SPLEEN; TULAREMIA; UP-REGULATION; VIRULENCE;

BACTERIA (MICROORGANISMS); FRANCISELLA TULARENSIS; FRANCISELLA TULARENSIS SUBSP. NOVICIDA; MURINAE; MUS;

EID: 79955598011     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2011.03.007     Document Type: Article

References (50)

1. Sjostedt A. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann N Y Acad Sci 2007, 1105:1-29.
2. Nano F.E., Schmerk C. The Francisella pathogenicity island. Ann N Y Acad Sci 2007, 1105:122-137.
3. Knapp S., Schultz M.J., van der Poll T. Pneumonia models and innate immunity to respiratory bacterial pathogens. Shock 2005, 24(Suppl. 1):12-18.
4. Martin G.S., Mannino D.M., Eaton S., Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554.
5. Munford R.S. Severe sepsis and septic shock: the role of gram-negative bacteremia. Annu Rev Pathol 2006, 1:467-496.
6. Riedemann N.C., Guo R.F., Ward P.A. Novel strategies for the treatment of sepsis. Nat Med 2003, 9:517-524.
7. Rittirsch D., Flierl M.A., Ward P.A. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008, 8:776-787.
8. Bianchi M.E. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007, 81:1-5.
9. Unsinger J., McDonough J.S., Shultz L.D., Ferguson T.A., Hotchkiss R.S. Sepsis-induced human lymphocyte apoptosis and cytokine production in "humanized" mice. J Leukoc Biol 2009, 86:219-227.
10. van Zoelen M.A., Yang H., Florquin S., Meijers J.C., Akira S., Arnold B., et al. Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 2009, 31:280-284.
11. Downs C.M., Buchele L., Edgar E.P. Studies on pathogenesis and immunity in tularemia; the pathogenesis of tularemia in the white rat. J Immunol 1949, 63:117-133.
12. Downs C.M., Woodward J.M. Studies on pathogenesis and immunity in tularemia; immunogenic properties for the white mouse of various strains of Bacterium tularense. J Immunol 1949, 63:147-163.
13. Sharma J., Li Q., Mishra B.B., Pena C., Teale J.M. Lethal pulmonary infection with Francisella novicida is associated with severe sepsis. J Leukoc Biol 2009, 86:491-504.
14. Sharma J., Li Q., Mishra B.B., Georges M.J., Teale J.M. Vaccination with an attenuated strain of Francisella novicida prevents T cell depletion and protects mice infected with the wildtype strain from severe sepsis. Infect Immun 2009, 77:4314-4326.
15. Mares C.A., Ojeda S.S., Morris E.G., Li Q., Teale J.M. Initial delay in the immune response to Francisella tularensis is followed by hypercytokinemia characteristic of severe sepsis and correlating with upregulation and release of damage-associated molecular patterns. Infect Immun 2008, 76:3001-3010.
16. Bopp C., Bierhaus A., Hofer S., Bouchon A., Nawroth P.P., Martin E., et al. Bench-to-bedside review: the inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care 2008, 12:201.
17. Sharma J., Li Q., Mishra B.B., Teale J.M. Lethal pulmonary infection with Francisella novicida causes depletion of alphabeta T cells from lungs. Cell Immunol 2009, 257:1-4.
18. Chang K.C., Unsinger J., Davis C.G., Schwulst S.J., Muenzer J.T., Strasser A., et al. Multiple triggers of cell death in sepsis: death receptor and mitochondrial-mediated apoptosis. FASEB J 2007, 21:708-719.
19. Takala A., Nupponen I., Kylanpaa-Back M.L., Repo H. Markers of inflammation in sepsis. Ann Med 2002, 34:614-623.
20. Herzum I., Renz H. Inflammatory markers in SIRS, sepsis and septic shock. Curr Med Chem 2008, 15:581-587.
21. Levi M. The coagulant response in sepsis. Clin Chest Med 2008, 29:627-642. viii.
22. Abraham E. Coagulation abnormalities in acute lung injury and sepsis. Am J Respir Cell Mol Biol 2000, 22:401-404.
23. Hatada T., Wada H., Nobori T., Okabayashi K., Maruyama K., Abe Y., et al. Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 2005, 94:975-979.
24. Bocchino M., Marruchella A., Saltini C. Immunogenetics of severe respiratory infections: models for the development of new therapeutic strategies. Respiration 2005, 72:449-457.
25. Conlan J.W., Chen W., Shen H., Webb A., KuoLee R. Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies. Microb Pathog 2003, 34:239-248.
26. Conlan J.W., Zhao X., Harris G., Shen H., Bolanowski M., Rietz C., et al. Molecular immunology of experimental primary tularemia in mice infected by respiratory or intradermal routes with type A Francisella tularensis. Mol Immunol 2008, 45:2962-2969.
27. Cole L.E., Elkins K.L., Michalek S.M., Qureshi N., Eaton L.J., Rallabhandi P., et al. Immunologic consequences of Francisella tularensis live vaccine strain infection: role of the innate immune response in infection and immunity. J Immunol 2006, 176:6888-6899.
28. Van Amersfoort E.S., Van Berkel T.J., Kuiper J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 2003, 16:379-414.
29. Bantel H., Schulze-Osthoff K. Cell death in sepsis: a matter of how, when, and where. Crit Care 2009, 13:173.
30. Hotchkiss R.S., Swanson P.E., Freeman B.D., Tinsley K.W., Cobb J.P., Matuschak G.M., et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999, 27:1230-1251.
31. Bosio C.M., Bielefeldt-Ohmann H., Belisle J.T. Active suppression of the pulmonary immune response by Francisella tularensis Schu4. J Immunol 2007, 178:4538-4547.
32. Everton Andrades M.R.C., Dal-Pizzol F. The role of free radicals in sepsis development. Front Biosci (Elite Ed) June 2009, 1:277-287.
33. Adib-Conquy M., Cavaillon J.M. Compensatory anti-inflammatory response syndrome. Thromb Haemost 2009, 101:36-47.
34. London N.R., Zhu W., Bozza F.A., Smith M.C., Greif D.M., Sorensen L.K., et al. Targeting Robo4-dependent slit signaling to survive the cytokine storm in sepsis and influenza. Sci Transl Med 2010, 2:23ra19.
35. Matsukawa A., Hogaboam C.M., Lukacs N.W., Lincoln P.M., Evanoff H.L., Strieter R.M., et al. Expression and contribution of endogenous IL-13 in an experimental model of sepsis. J Immunol 2000, 164:2738-2744.
36. Zhang H., Moochhala S.M., Bhatia M. Endogenous hydrogen sulfide regulates inflammatory response by activating the ERK pathway in polymicrobial sepsis. J Immunol 2008, 181:4320-4331.
37. Porter K.J., Gonipeta B., Parvataneni S., Appledorn D.M., Patial S., Sharma D., et al. Regulation of lipopolysaccharide-induced inflammatory response and endotoxemia by beta-arrestins. J Cell Physiol 2010.
38. Schuetz P., Christ-Crain M., Morgenthaler N.G., Struck J., Bergmann A., Muller B. Circulating precursor levels of endothelin-1 and adrenomedullin, two endothelium-derived, counteracting substances, in sepsis. Endothelium 2007, 14:345-351.
39. Qin S., Wang H., Yuan R., Li H., Ochani M., Ochani K., et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006, 203:1637-1642.
40. Zanotti-Cavazzoni S.L., Hollenberg S.M. Cardiac dysfunction in severe sepsis and septic shock. Curr Opin Crit Care 2009.
41. Hall W.C., Kovatch R.M., Schricker R.L. Tularaemic pneumonia: pathogenesis of the aerosol-induced disease in monkeys. J Pathol 1973, 110:193-201.
42. Sriskandan S., Altmann D.M. The immunology of sepsis. J Pathol 2008, 214:211-223.
43. Haimovitz-Friedman A., Cordon-Cardo C., Bayoumy S., Garzotto M., McLoughlin M., Gallily R., et al. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J Exp Med 1997, 186:1831-1841.
44. Tsokos M., Pufe T., Paulsen F., Anders S., Mentlein R. Pulmonary expression of vascular endothelial growth factor in sepsis. Arch Pathol Lab Med 2003, 127:331-335.
45. Adib-Conquy M., Cavaillon J.M. Stress molecules in sepsis and systemic inflammatory response syndrome. FEBS Lett 2007, 581:3723-3733.
46. Ehrchen J.M., Sunderkotter C., Foell D., Vogl T., Roth J. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 2009, 86:557-566.
47. Foell D., Roth J. Proinflammatory S100 p.oteins in arthritis and autoimmune disease. Arthritis Rheum 2004, 50:3762-3771.
48. Foell D., Wittkowski H., Vogl T., Roth J. S100 p.oteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007, 81:28-37.
49. Hajjar A.M., Harvey M.D., Shaffer S.A., Goodlett D.R., Sjostedt A., Edebro H., et al. Lack of in vitro and in vivo recognition of Francisella tularensis subspecies lipopolysaccharide by Toll-like receptors. Infect Immun 2006, 74:6730-6738.
50. Zhu S., Ashok M., Li J., Li W., Yang H., Wang P., et al. Spermine protects mice against lethal sepsis partly by attenuating surrogate inflammatory markers. Mol Med 2009, 15:275-282.